Harmony Biosciences Holdings (HRMY) Preferred Stock Liabilities (2019 - 2020)
Harmony Biosciences Holdings recorded quarterly Preferred Stock Liabilities of $434.0 million in Q2 2020, up 5.53% quarter-over-quarter from $411.3 million in Q4 2019.
Harmony Biosciences Holdings' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $434.0 million for Q2 2020.
- In Q2 2020, Preferred Stock Liabilities changed N/A year-over-year to $434.0 million; the TTM figure through Jun 2020 stood at $434.0 million (changed N/A YoY), while the FY2019 annual figure was $411.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $434.0 million for Q2 2020 at Harmony Biosciences Holdings, up from $411.3 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $434.0 million in Q2 2020 to a low of $400.9 million in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Harmony Biosciences Holdings | 1.83 Bn | 1.19 Bn | 170.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 434.01 Mn |
| Dec 31, 2019 | 411.28 Mn |
| Sep 30, 2019 | 400.88 Mn |